Top

Published in:

Open Access 01-01-2022 | Osteoarthrosis | Original Research Article

Cost-Effectiveness Analysis of the Treatment Strategies with or without Opioid Medications in Surgery-Eligible Patients with Osteoarthritis in Japan

Authors: Tomoyuki Takura, Akira Yuasa, Naohiro Yonemoto, Sven Demiya, Hiroyuki Matsuda, Nozomi Ebata, Koichi Fujii, Muneaki Ishijima

Published in: PharmacoEconomics - Open | Issue 1/2022

Abstract

Aim

The aim of this study was to evaluate the cost effectiveness of treatment strategies without opioid medications (non-opioid treatment strategy) versus strategies with opioid medications (opioid treatment strategy) among surgery-eligible patients with osteoarthritis (OA) of the knee or hip in Japan.

Materials and Methods

We built a Markov cohort model to evaluate outcomes for the treatment strategies in surgery-eligible patients aged ≥ 65 years with OA of the knee or hip in Japan. The opioid treatment strategy as an intervention includes a health state with opioid medication in the treatment pathway. On the other hand, for the non-opioid treatment strategy, there is no health state with opioid medication. A targeted literature review and database analysis were conducted to identify and define the values of the variables included in the model. The time horizon was set to 30 years, and a 2% discount was applied for cost and quality-adjusted life-years (QALYs). Sensitivity analysis and scenario analysis were performed in the model. The outcomes were QALYs and the incremental cost-effectiveness ratio (ICER).

Results

In the base-case analysis, the non-opioid treatment strategy was dominant over the opioid treatment strategy and associated with an incremental cost and QALYs of − 53,878 JPY (− 499 USD) and 0.03 QALYs, respectively, in patients with knee OA, and − 54,129 JPY (− 502 USD) and 0.02 QALYs, respectively, in patients with hip OA. One-way sensitivity analysis showed the ICER was most sensitive to the QALY for opioid monotherapy. Probabilistic sensitivity analyses showed a high degree of uncertainty associated with the results.

Limitations

Study limitations included assumptions related to transition probabilities of the health states, and a lack of Japanese-specific data for transition probabilities, incidence of adverse events and utility values.

Conclusions

This study suggests that the non-opioid treatment strategy is cost effective compared with the opioid treatment strategy in the management of surgery-eligible patients with OA of the knee or hip. However, this final conclusion may not be accurate as the methodology is heavily reliant on assumptions.

Available only for authorised users

Bannuru RR, Schmid CH, Kent DM, Vaysbrot EE, Wong JB, McAlindon TE. Comparative effectiveness of pharmacologic interventions for knee osteoarthritis: a systematic review and network meta-analysis. Ann Intern Med. 2015;162(1):46–54.CrossRef

Sadosky AB, DiBonaventura M, Cappelleri JC, Ebata N, Fujii K. The association between lower back pain and health status, work productivity, and health care resource use in Japan. J Pain Res. 2015;8:119.PubMedPubMedCentral

Jordan K, Arden N, Doherty M, Bannwarth B, Bijlsma J, Dieppe P, et al. EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis. 2003;62(12):1145–55.CrossRef

Muraki S, Akune T, Oka H, En-Yo Y, Yoshida M, Saika A, et al. Association of radiographic and symptomatic knee osteoarthritis with health-related quality of life in a population-based cohort study in Japan: the ROAD study. Osteoarthr Cartil. 2010;18(9):1227–34.CrossRef

Rice D, McNair P, Huysmans E, Letzen J, Finan P. Best evidence rehabilitation for chronic pain part 5: osteoarthritis. J Clin Med. 2019;8(11):1769. https://doi.org/10.3390/jcm8111769.CrossRefPubMedCentral

Brosseau L, Yonge KA, Robinson V, Marchand S, Judd M, Wells G, et al. Thermotherapy for treatment of osteoarthritis. Cochrane Database Syst Rev. 2003;2003(4):CD004522. https://doi.org/10.1002/14651858.CD004522.CrossRefPubMedCentral

Dawson J, Linsell L, Zondervan K, Rose P, Randall T, Carr A, et al. Epidemiology of hip and knee pain and its impact on overall health status in older adults. Rheumatology. 2004;43(4):497–504.CrossRef

Muraki S, Akune T, Oka H, Mabuchi A, En-Yo Y, Yoshida M, et al. Association of occupational activity with radiographic knee osteoarthritis and lumbar spondylosis in elderly patients of population-based cohorts: a large-scale population-based study. Arthritis Care Res Off J Am Coll Rheumatol. 2009;61(6):779–86.CrossRef

Inoue K, Wicart P, Kawasaki T, Huang J, Ushiyama T, Hukuda S, et al. Prevalence of hip osteoarthritis and acetabular dysplasia in French and Japanese adults. Rheumatology. 2000;39(7):745–8.CrossRef

10.

Akazawa M, Mimura W, Togo K, Ebata N, Harada N, Murano H, et al. Patterns of drug treatment in patients with osteoarthritis and chronic low back pain in Japan: a retrospective database study. J Pain Res. 2019;12:1631.CrossRef

11.

Japanese Orthopaedic Association (JOA) Committee. OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OASRI evidence-based, expert consensus guidelines adapted to Japanese by Japanese Orthopaedic Association (JOA) Committee on Clinical Practice Guideline on the Management of Osteoarthritis of the Knee 2012.

12.

Kolasinski SL, Neogi T, Hochberg MC, Oatis C, Guyatt G, Block J, et al. 2019 American College of Rheumatology/arthritis foundation guideline for the management of osteoarthritis of the hand, hip, and knee. Arthritis Care Res (Hoboken). 2020;72(2):149–62. https://doi.org/10.1002/acr.24131.CrossRef

13.

Onishi E, Kobayashi T, Dexter E, Marino M, Maeno T, Deyo RA. Comparison of opioid prescribing patterns in the United States and Japan: primary care physicians’ attitudes and perceptions. J Am Board Fam Med. 2017;30(2):248–54.CrossRef

14.

Kanai A. Issues of opioid analgesics and expectations of buprenorphine. Locomot Pain Front. 2017;6(2):52–9.

15.

Hootman JM, Helmick CG, Barbour KE, Theis KA, Boring MA. Updated projected prevalence of self-reported doctor-diagnosed arthritis and arthritis-attributable activity limitation among US adults, 2015–2040. Arthritis Rheumatol. 2016;68(7):1582–7. https://doi.org/10.1002/art.39692.CrossRefPubMedPubMedCentral

16.

United States Bone and Joint Initiative. The burden of musculoskeletal diseases in the United States (BMUS) Forthcoming Rosemont, IL. https://www.boneandjointburden.org/fourth-edition/iiib10/osteoarthritis.

17.

Itoh H, Saito T, Nojiri S, Hiratsuka Y, Yokoyama K. National burden of the pharmaceutical cost of wet compresses and its cost predictors: nationwide cross-sectional study in Japan. Heal Econ Rev. 2019;9(1):20. https://doi.org/10.1186/s13561-019-0238-6.CrossRef

18.

Katz JN, Smith SR, Collins JE, Solomon DH, Jordan JM, Hunter DJ, et al. Cost-effectiveness of nonsteroidal anti-inflammatory drugs and opioids in the treatment of knee osteoarthritis in older patients with multiple comorbidities. Osteoarthr Cartil. 2016;24(3):409–18.CrossRef

19.

Smith SR, Katz JN, Collins JE, Solomon DH, Jordan JM, Suter LG, et al. Cost-effectiveness of tramadol and oxycodone in the treatment of knee osteoarthritis. Arthritis Care Res (Hoboken). 2017;69(2):234–42. https://doi.org/10.1002/acr.22916.CrossRef

20.

Valdes A, Stocks J. Osteoarthritis and ageing. Eur Med J. 2018;3(1):116–23.

21.

Zhang W, Moskowitz R, Nuki G, Abramson S, Altman RD, Arden N, et al. OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthr Cartil. 2008;16(2):137–62.CrossRef

22.

Center for Outcomes Research and Economic Evaluation for Health, National Institute of Public Health (C2H). Guideline for preparing cost-effectiveness evaluation to the Central Social Insurance Medical Council. Version 2.0; approved 20 February 2019. https://c2h.niph.go.jp/tools/guideline/guideline_en.pdf. Accessed 15 July 2020.

23.

Hasegawa M, Komoto S, Shiroiwa T, Fukuda T. Formal implementation of cost-effectiveness evaluations in japan: a unique health technology assessment system. Value Health. 2020;23(1):43–51. https://doi.org/10.1016/j.jval.2019.10.005.CrossRefPubMed

24.

THE WORLD BANK. Life expectancy at birth, total (years). 2020. https://data.worldbank.org/indicator/SP.DYN.LE00.IN. Accessed 15 July 2020.

25.

Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS)–explanation and elaboration: a report of the ISPOR health economic evaluation publication guidelines good reporting practices task force. Value Health. 2013;16(2):231–50. https://doi.org/10.1016/j.jval.2013.02.002.CrossRefPubMed

26.

Nakamura M. Utilization of MDV data and data quality control. Jpn J Pharmacoepidemiol Yakuzai Ekigaku. 2016;21(1):23–5. https://doi.org/10.3820/jjpe.21.23.CrossRef

27.

Zhang B, Lin H, Hunter DJ, Neogi T, Wise B, Choy E, et al. A multistate transition model for osteoarthritis pain change. Commun Stat Theory Methods. 2009;38(18):3297–306.CrossRef

28.

Piscitelli P, Iolascon G, Di Tanna G, Bizzi E, Chitano G, Argentiero A, et al. Socioeconomic burden of total joint arthroplasty for symptomatic hip and knee osteoarthritis in the Italian population: a 5-year analysis based on hospitalization records. Arthritis Care Res (Hoboken). 2012;64(9):1320–7. https://doi.org/10.1002/acr.21706.CrossRef

29.

Ministry of Health, Labour and Welfare. Abridged life tables for Japan 2018. 2019. https://www.mhlw.go.jp/english/database/db-hw/lifetb18/index.html. Accessed 15 July 2020.

30.

Hara M, Hayashi K, Kitamura T, Honda M, Tamaki M. A nationwide randomized, double-blind, placebo-controlled physicians’ trial of loxoprofen for the treatment of fatigue, headache, and nausea after hangovers. Alcohol. 2020;84:21–5. https://doi.org/10.1016/j.alcohol.2019.10.006.CrossRefPubMed

31.

Ushida T, Matsui D, Inoue T, Yokoyama M, Takatsuna H, Matsumoto T, et al. Recent prescription status of oral analgesics in Japan in real-world clinical settings: retrospective study using a large-scale prescription database. Expert Opin Pharmacother. 2019;20(16):2041–52. https://doi.org/10.1080/14656566.2019.1651840.CrossRefPubMed

32.

Japanese Society for Palliative Medicine. Clinical guidelines for cancer pain management. 2014.

33.

García-Pérez L, Ramos-García V, Serrano-Aguilar P, Pais-Brito JL, de Mendoza MA, Martín-Fernández J, et al. EQ-5D-5 L utilities per health states in Spanish population with knee or hip osteoarthritis. Health Qual Life Outcomes. 2019;17(1):164.CrossRef

34.

Marra CA, Grubisic M, Cibere J, Grindrod KA, Woolcott JC, Gastonguay L, et al. Cost-utility analysis of a multidisciplinary strategy to manage osteoarthritis of the knee: economic evaluation of a cluster randomized controlled trial study. Arthritis Care Res. 2014;66(6):810–6.CrossRef

35.

Taguchi Y, Inoue Y, Kido T, Arai N. Treatment costs and cost drivers among osteoporotic fracture patients in Japan: a retrospective database analysis. Arch Osteoporos. 2018;13(1):45.CrossRef

36.

Kimura K, Kimura T, Ishihara M, Nakagawa Y, Nakao K, Miyauchi K, et al. JCS 2018 guideline on diagnosis and treatment of acute coronary syndrome. Circ J. 2019;83(5):1085–196.CrossRef

37.

Powers WJ, Rabinstein AA, Ackerson T, Adeoye OM, Bambakidis NC, Becker K, et al. 2018 guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2018;49(3):e46–99.CrossRef

38.

Tsutsui H, Isobe M, Ito H, Okumura K, Ono M, Kitakaze M, et al. JCS 2017/JHFS 2017 guideline on diagnosis and treatment of acute and chronic heart failure-digest version-. Circ J. 2019;83(10):2084–184.CrossRef

39.

Hashiguchi M, Yamauchi N, Uchikura T, Mochizuki M. Cost comparative analysis of drug therapy for non-steroidal anti-inflammatory drug (NSAID)-induced gastric ulcer in Japan. Yakugaku Zasshi J Pharm Soc Jpn. 2008;128(4):585–94.CrossRef

40.

Shiraishi Y, Kohsaka S, Sato N, Takano T, Kitai T, Yoshikawa T, et al. 9-Year trend in the management of acute heart failure in japan: a report from the national consortium of acute heart failure registries. J Am Heart Assoc. 2018;7(18):e008687. https://doi.org/10.1161/jaha.118.008687.CrossRefPubMedPubMedCentral

41.

Kinjo K, Sato H, Nakatani D, Mizuno H, Shimizu M, Hishida E, et al. Predictors of length of hospital stay after acute myocardial infarction in Japan. Circ J. 2004;68(9):809–15. https://doi.org/10.1253/circj.68.809.CrossRefPubMed

42.

Yagi M, Yasunaga H, Matsui H, Morita K, Fushimi K, Fujimoto M, et al. Impact of rehabilitation on outcomes in patients with ischemic stroke: a nationwide retrospective cohort study in Japan. Stroke. 2017;48(3):740–6. https://doi.org/10.1161/strokeaha.116.015147.CrossRefPubMed

43.

Ministry of Health, Labour and Welfare. Various information of medical fee. 2020. https://shinryohoshu.mhlw.go.jp/shinryohoshu/kaitei/. Accessed 15 July 2020.

44.

Bank of Japan. Turnover of swap (US Dollar/Yen). 2020. https://www.boj.or.jp/statistics/market/forex/fxdaily/index.htm/. Accessed 15 July 2020.

45.

ORGANISATION FOR ECONOMIC CO-OPERATION AND DEVELOPMENT. Purchasing power parities (PPP) statistics purchasing power parities for GDP and related indicators. OECD.Stat. 2020. https://stats.oecd.org/Index.aspx?DataSetCode=CPL#. Accessed 15 July 2020.

46.

Briggs A, Claxton K, Sculpher M. Decision modelling for health economic evaluation. Oxford University Press, 2006.

Title: Cost-Effectiveness Analysis of the Treatment Strategies with or without Opioid Medications in Surgery-Eligible Patients with Osteoarthritis in Japan
Authors: Tomoyuki Takura
Akira Yuasa
Naohiro Yonemoto
Sven Demiya
Hiroyuki Matsuda
Nozomi Ebata
Koichi Fujii
Muneaki Ishijima
Publication date: 01-01-2022
Publisher: Springer International Publishing
Keywords: Osteoarthrosis
Opioids
Opioids
Tramadol
Osteoarthrosis
Published in: PharmacoEconomics - Open / Issue 1/2022
Print ISSN: 2509-4262
Electronic ISSN: 2509-4254
DOI: https://doi.org/10.1007/s41669-021-00292-5

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Cost-Effectiveness Analysis of the Treatment Strategies with or without Opioid Medications in Surgery-Eligible Patients with Osteoarthritis in Japan

Abstract

Aim

Materials and Methods

Results

Limitations

Conclusions

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Aim

Materials and Methods

Results

Limitations

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2022

Acknowledgement to Referees

A Real-World Assessment of Outcomes, Health Resource Utilization, and Costs Associated with Cerebral Edema in US Patients with Large Hemispheric Infarction

Economic Analysis of the CADScor System for Ruling Out Coronary Artery Disease in England

Cost Effectiveness of a Cultural Physical Activity Intervention to Reduce Blood Pressure Among Native Hawaiians with Hypertension

Cost-Effectiveness of Inotuzumab Ozogamicin Compared to Standard of Care Chemotherapy for Treating Relapsed or Refractory Acute Lymphoblastic Leukaemia Patients in Norway and Sweden

The Utility of Economic Measures to Quantify the Burden of Tinnitus in Affected Individuals: A Scoping Review